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Five subjects with mucopolysaccharidosis type I and symptomatic
cervical spinal stenosis received intrathecal laronidase in a 4-
month pilot study and/or a 12-month extension study [1]. Clinical
descriptions of study subjects, nonserious adverse events, indivi-
dual data tables, and scoring system methods are provided. There
were ten nonserious adverse events that occurred in more than
one study subject. Somatosensory evoked potentials were absent
in two subjects and normal in two subjects, limiting their utility as
an endpoint. There were no significant changes in magnetic
resonance imaging of cervical spinal cord or brain, pulmonary
function tests, or cerebrospinal fluid opening pressure. These data
are presented along with the scoring methods used in evaluation
of the study subjects.
& 2015 Published by Elsevier Inc. This is an open access article
under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).is an open access article under the CC BY license
/j.ymgme.2015.07.005
).
P.I. Dickson et al. / Data in Brief 5 (2015) 71–7672Specifications tableSubject area Biology
More specific
subject areaInborn errors of metabolismType of data Text files, tables, figures
How data was
acquiredClinical evaluations, magnetic resonance imaging, nerve conduction studies, spirography, lumbar spinal
punctureData format Raw, processed
Experimental factors Subjects were treated with intrathecal laronidase, and pre- and post-treatment data are presented
Experimental
featuresClinical data are presented descriptively. Adverse events were tabulated based on subject reporting.
Magnetic resonance imaging data were scored for spinal cord compression, hydrocephalus, white matter
hyperintensities, and cystic or cribriform changes. Pulmonary function tests, cerebrospinal fluid opening
pressure and somatosensory evoked potentials were obtained in standard clinical fashion.Data source location N/A (multicenter clinical trial)
Data accessibility N/AValue of the data There are very few clinical data reports of cervical spinal stenosis due to mucopolysaccharidosis
type I, or attempts at treatment. Quantitative as well as qualitative data are presented.
 The data may inform future studies of intrathecal enzyme replacement therapy for lysosomal
storage disorders.
1. Experimental design, materials and methods
1.1. Subjects
Study subjects are narratively described in data file 1. They were treated with intrathecal
laronidase as described in Ref. [1].
1.2. Measures of safety
To evaluate possible adverse effects of study treatments, participants had physical and neurologic
examination before and after each study treatment. All new physical complaints were evaluated and
recorded including their severity and attribution to study treatments. Table 1 lists nonserious adverse
events.
1.3. Objective measures of efficacy
Response to treatment was assessed using a combination of subjective and objective measures. We
evaluated somatosensory evoked potentials in the upper and lower extremity as per [2]. Results are
shown in Table 2. MRI of brain and spinal cord were obtained to assess degree of cord compression and
measurement of meningeal thickness was taken. MRI were performed using a 1.5-Tesla GE LX9.1. Brain
imaging included sagittal T1-weighted, axial FLAIR, axial T2-weighted and axial diffusion-weighted
images. Sagittal T1- and T2-weighted images of the whole spine and axial T1-weighted images of the
cervical spine were obtained. Axial T1-weighted studies of the cervical spine were used to score spinal
cord compression according to the methods of Houten and Cooper [3]. Brain images were evaluated for
Table 1
Nonserious adverse events.
Events occurring in 41 study subject Events occurring in 1 study subject
Headache Anemia
Neck pain Nausea
Hypoxemia Pneumonia
Desaturation during procedure Tingling
Elevated CSF opening pressure Decreased sensation right hand
Back pain Blurred vision
Myoclonic-like twitches Decreased visual acuity
Diarrhea/gastroenteritis Weakness
Upper respiratory infection Insomnia
Fever Elevated serum phosphorus
Decreased serum protein
Decreased serum albumin
Elevated CSF protein
Elevated CSF leukocyte count
Hip and thigh pain
Pruritus (with fentanyl)
Pneumocephaly
Dizziness
Gradual turning outward of right foot hampering walking and balance
Abdominal pain
Clumsiness in leg
Dyspnea and cough
Joint Pain
Hand cramps
Perineal muscle cramps
Tachycardia at rest
Sore throat
“Shaking while laying down”/“tremor”
Abdominal cramping / dysmenorrhea
Facial flushing
Urinary urgency
Influenza
Leg weakness
Urticaria
Melena
Malaise
CSF: cerebrospinal fluid.
Table 2
Somatosensory evoked potentials. Intrasubject change (absolute) in latency (ms) during the pilot and extension studies for
subjects with both baseline and end-study measurements.
4-Month pilot study 12-Month extension study
Subject number: 1 3 5 5
Median nerve
N9-N13A Absent 0.80 Absent Absent
N9-N13B Absenta 0.60 Absent Absent
N9-P13 Absent 1.10 Absent Absent
N13A-N20 Absent 0.40 Absenta 6.5
Posterior tibial nerve
N22-P30 Absent 1.00 Absent Absent
N22-P40 Absent 0.80 2.40 8.8
a N9–N13B was present at baseline in subject 1 at a latency of 3.30 ms but absent at the Day 120 visit. N13A-N20 was
present in subject 5 at the Day 120 visit at a latency of 10.8 ms but absent at baseline. Subject 2 did not have baseline
measurements (the subject was not enrolled in the pilot study). Subject 4 did not have day 120 measurements (termination of
participation due to subject death).
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Table 3
MRI cervical spinal cord compression (maximum grade).
4-Month pilot study 12-Month extension study
Subject number Baseline End of study Baseline Six months End of study
1 3 3 3 N/A N/A
2 N/A N/A 3 3 N/A
3 2 to 3 2 to 3 N/A N/A N/A
4 2 N/A N/A N/A N/A
5 1 ND 1 2 2
Grading system: 0, 3601 cushion of CSF around cord; 1, loss of CSF cushion w/o indentation of the cord but may have slight
anterior cord flattening; 2, mild spinal cord compression; and 3, severe cord compression.
Table 4
Brain MRI abnormal T2 signal intensity.
4-Month pilot study 12-Month extension study
Subject number Baseline End of Study Baseline Six months End of study
1 2 2 2 N/A N/A
2 N/A N/A 0 0 N/A
3 0 0 N/A N/A N/A
4 2 N/A N/A N/A N/A
5 1 1 1 2 2
Grading system: score signal changes on T2-weighted images as 0, absent; 1, patchy and confined to the periventricular area; 2,
patchy but in other white matter areas as well as periventricular; and 3, diffuse.
Table 5
Brain MRI enlargement of perivascular spaces.
4-Month pilot study 12-Month extension study
Subject number Baseline End of study Baseline Six months End of study
1 2 2 3 N/A N/A
2 N/A N/A 1 1 N/A
3 0 0 N/A N/A N/A
4 2 N/A N/A N/A N/A
5 3 2 3 2 2
Grading system: 0, no enlargement; 1, o3 mm enlargement; 2, between 3 and 8 mm enlargement; and 3, 48 mm
enlargement.
Table 6
Brain MRI frontal-occipital horn ratio.
4-Month pilot study 12-Month extension study
Subject number Baseline End of study Baseline Six months End of study
1 0.418 0.406 0.368 N/A N/A
2 N/A N/A 0.472 0.472 N/A
3 0.767 0.752 N/A N/A N/A
4 0.547 N/A N/A N/A N/A
5 0.385 0.385 0.385 0.588 0.598
FOR is calculated as follows: measure a ratio between the frontal and occipital horns of the lateral ventricle using the maximum
distance between the outer borders of the frontal horns added to the distance between the outer borders of occipital horns,
then divide by twice the maximum biparietal diameter.
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Table 7
Brain MRI atrophy and megacisterna magna.
4-Month pilot study 12-Month extension study
Subject number Baseline End of study Baseline Six months End of study
Brain atrophy
1 1 1 1 N/A N/A
2 N/A N/A 0 0 N/A
3 0 0 N/A N/A N/A
4 0 N/A N/A N/A N/A
5 1 1 1 1 1
Megacisterna magna
1 1 1 1 N/A N/A
2 N/A N/A 1 1 N/A
3 1 1 N/A N/A N/A
4 0 N/A N/A N/A N/A
5 0 0 0 0 0
Grading system: 0, absent; 1, mild; 2, moderate; and 3, severe.
Fig. 1. Pulmonary function tests. Subjects in the extension study underwent pulmonary function tests by spirometry at
each visit.
P.I. Dickson et al. / Data in Brief 5 (2015) 71–76 75abnormal signal intensity in T2, enlargement of perivascular spaces, and ventricular size as per Matheus
et al. [4]. Results are shown in Tables 3–7. Subjects enrolled in the extension study also underwent
pulmonary function testing using spirometry (Fig. 1). Cerebrospinal fluid glycosaminoglycans were
Fig. 2. CSF opening pressure. We measured opening pressure prior to each dose of intrathecal laronidase by manometry at the
level of the right atrium. We did not obtain opening pressure measurements at Days 0 and 30 for subject 1 due to technical
issues performing the lumbar puncture during those visits. Subjects 2–4 had a history of hydrocephalus and implanted CSF
drainage shunts.
P.I. Dickson et al. / Data in Brief 5 (2015) 71–7676measured at Seattle Children's Hospital using a clinically-available test (Fig. 2). The laboratory uses a
dimethylene blue dye-binding assay to quantitate total glycosaminoglycans [5]. Functional Indepen-
dence Measure (FIM) score and Japanese Orthopedic Association (JOA) score measures were used to
assess any changes in functional status and myelopathy. Results are shown in Fig. 1 of Ref. [1]. Scoring
criteria for JOA and FIM are given in data files 2 and 3. The grading systems that were used to indicate
the severity of spinal cord compression and brain imaging findings are given in data file 4.Appendix A. Supporting information
Supplementary data associated with this article can be found in the online version at http://dx.doi.
org/10.1016/j.dib.2015.08.004.References
[1] P. Dickson, I. Kaitila, P. Harmatz, A. Mlikotic, A. Chen, A. Victoroff, M. Passage, J. Madden, S. Le, D. Naylor, Safety of laronidase
delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I, Mol. Genet. Metab. (2015).
(PMID 26260077).
[2] R. Boor, E. Miebach, K. Brþþhl, M. Beck, Abnormal somatosensory evoked potentials indicate compressive cervical
myelopathy in mucopolysaccharidoses, Neuropediatrics 31 (2000) 122–127.
[3] J.K. Houten, P.R. Cooper, Laminectomy and posterior cervical plating for multilevel cervical spondylotic myelopathy and
ossification of the posterior longitudinal ligament: effects on cervical alignment, spinal cord compression, and neurological
outcome, Neurosurgery 52 (2003) 1081–1088.
[4] M.G. Matheus, M. Castillo, J.K. Smith, D. Armao, D. Towle, J. Muenzer, Brain MRI findings in patients with
mucopolysaccharidosis types I and II and mild clinical presentation, Neuroradiology 46 (2004) 666–672.
[5] C.B. Whitley, K.A. Draper, C.M. Dutton, P.A. Brown, S.L. Severson, L.A. France, Diagnostic test for mucopolysaccharidosis. II.
Rapid quantification of glycosaminoglycan in urine samples collected on a paper matrix, Clin. Chem. 35 (1989) 2074–2081.
